Frances Levin

Credentials: · ·

History

Translational Clinical Research Fellowship on Substance Use Disorders
National Institute on Drug Abuse · T32
Contact PI · $8.6M · Columbia University Health Sciences
1993–2028
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
National Institute on Drug Abuse · U01
PI · $8.7M · Phoenix Pharmalabs, Inc.
2022–2027
Augmenting Cognitive-Behavioral Therapy with rTMS of the Medial Prefrontal and Anterior Cingulate Cortices for the Treatment of Cocaine Use Disorder
National Institute on Drug Abuse · UG3
PI · $1.5M · New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, Inc
2023–2027
Phase 1 and 2 Studies of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal
National Institute on Drug Abuse · UG3
Contact PI · $3.3M · New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, Inc
2022–2027

Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)
Principal investigator · Completed · Phase 2
Aelis Farma
2022–2024
Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder
Principal investigator · Completed · Phase 2
Frances R Levin
2020–2023
Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
Principal investigator · Completed · Phase 2
New York State Psychiatric Institute
2019–2021
Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
Principal investigator · Completed · Phase 2, Phase 3
New York State Psychiatric Institute
2017–2019